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ABSTRACT
Background: Proximal esophageal cancer (EC) is commonly treated with definitive chemoradiation
(CRT). The radiation dose and type of chemotherapy backbone are still under debate. The objective of
this study was to compare the treatment outcomes of contemporary CRT regimens.
Material and Methods: In this retrospective observational cohort study, we included patients with
locally advanced squamous cell cancer of the proximal esophagus, from 11 centers in the Netherlands,
treated with definitive CRT between 2004 and 2014. Each center had a preferential CRT regimen,
based on cisplatin (Cis) or carboplatin-paclitaxel (CP) combined with low (50.4Gy) or high (>50.4 Gy)
dose radiotherapy (RT). Differences in overall survival (OS) between CRT regimens were assessed using
a fully adjusted Cox proportional hazards and propensity score (PS) weighted model. Safety profiles
were compared using a multilevel logistic regression model.
Results: Two hundred patients were included. Fifty-four, 39, 95, and 12 patients were treated with Cis-
low-dose RT, Cis-high-dose RT, CP-low-dose RT, and CP-high-dose RT, respectively. Median follow-up
was 62.6months (95% CI: 47.9–77.2months). Median OS (21.9months; 95% CI: 16.9–27.0months) was
comparable between treatment groups (logrank p¼ .88), confirmed in the fully adjusted and PS
weighted model (p> .05). Grades 3–5 acute adverse events were less frequent in patients treated with
CP-low-dose RT versus Cis-high-dose RT (OR 3.78; 95% CI: 1.31–10.87; p¼ .01). The occurrence of
grades 3–5 late toxicities was not different between treatment groups.
Conclusion: Our study was unable to demonstrate a difference in OS between the CRT regimens,
probably related to the relatively small sample size. Based on the superior safety profile, carboplatin
and paclitaxel-based CRT regimens are preferred in patients with locally advanced proximal EC.
ARTICLE HISTORY
Received 6 November 2019
Accepted 4 April 2020
Introduction
Ten percent of all esophageal cancers (ECs) are located in
the proximal part of the esophagus, which consists of the
cervical and upper thoracic segment [1]. Proximal EC is chal-
lenging to treat due to the vicinity of vital structures includ-
ing the larynx, cricoid, and trachea, which are frequently
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infiltrated. Furthermore, patients with proximal EC often have
locoregional lymph node metastases at the time of diagnosis
[2]. Most patients with proximal EC are thus being diagnosed at
an unresectable stage. In others, surgical treatment would impli-
cate mutilating resections, with a high risk of major complica-
tions and an extensive impact on a patient’s quality of life [3–5].
As shown in the Radiation Therapy Oncology Group
(RTOG) 85-01 trial, a nonsurgical approach of definitive che-
moradiation (CRT) provides a significant survival advantage
over monomodality radiotherapy (RT) in patients with EC [6].
Hence, CRT is the standard treatment modality in patients
with proximal EC recommended by the National
Comprehensive Cancer Network (NCCN) and European
Society for Medical Oncology (ESMO) [7,8]. However, there
are no data on the most effective CRT regimen in proximal
EC [9]. Hence, physicians use either established regimens for
the treatment of head and neck squamous cell carcinoma
(HNSCC) due to similarities in location, histology, and molecu-
lar features [10], or regimens used in the management of
patients with lower EC [9]. The most frequently used CRT regi-
men for HNSCC is 66–70Gy RT, with concurrent cisplatin (Cis)
at a minimum cumulative dose of 200mg/m2 body surface
intravenously in a 7-week treatment period [11,12].
In EC, the radiation dose and type of chemotherapy back-
bone in CRT are still under debate. In the definitive CRT set-
ting, radiation doses of 50–50.4 Gy are recommended to
cancers originating in the esophagus [6–8]. NCCN guidelines
state that higher doses of RT (60–66Gy) may be appropriate
for cancers in the proximal esophagus, although sufficient
data to substantiate this statement are lacking [7].
Chemotherapy schemes containing Cis and 5-fluorouracil (5-
FU) have long been the standard in CRT regimens for EC
[6,8,13]. CRT with paclitaxel plus 5-FU did not improve survival
over Cis and 5-FU-based CRT [14]. The CROSS trial [15] demon-
strated acceptable adverse event rates for carboplatin-paclitaxel
(CP)-based pre-operative CRT in patients with EC, with a patho-
logic complete response rate of 49% in patients with squamous
cell EC, which was higher than previously observed in Cis-5-FU
regimens [16–18]. These results have led to the use of CP in
definitive CRT schedules [19]. Accordingly, CRT regimens for EC
with Cis or CP are recommended by the NCCN and ESMO [7,8].
Results from a small comparative study in the definitive treat-
ment of EC support implementing CP-based CRT, showing com-
parable survival and a more favorable safety profile in patients
treated with CP compared with Cis-based CRT [20]. However,
this study did not include cervical EC, and only a minority of
patients were treated with a radiation dose exceeding 50.4Gy.
We hypothesized that patients with proximal EC treated with
CP-based definitive CRT with low-dose RT have the best out-
come in terms of adverse events, and comparable survival
when compared with Cis-based and high-dose RT schemes.
We conducted a propensity-score weighted study to
evaluate overall survival (OS) and safety of four contempor-
ary CRT regimens in patients with proximal EC.
Material and methods
This multicenter, retrospective, observational study was con-
ducted in 11 centers in The Netherlands. Patients were
eligible if they were 18 years of age or older, diagnosed
with squamous cell cancer of the proximal esophagus (i.e.
<24 cm from incisor teeth [21]), stage cT1NþM0 or cT2-
4N0-3M0, and started with CRT treatment with a curative
intent, between January 2004 and December 2014. Tumor
staging was performed according to the TNM 6th or 7th
edition based on date of diagnosis [21,22]. Patients with
supraclavicular lymph node metastasis were included, as
these lymph nodes were considered to be locoregional
node metastasis [23]. Patient informed consent was waived
by the Medical Ethics Board azM/UM due to the retrospect-
ive nature of the study (METC 15-4-012). The study was
approved by the scientific committee of the Dutch Upper
GI Cancer Group (DUCG), and the Dutch Head and Neck
Oncology Cooperative Group (NWHHT 2017-01). The data
that support the findings of this study are available from
the corresponding author upon request.
Treatment
Patients received a CRT regimen consisting of cisplatin (Cis)-
based chemotherapy with low (Cis-low-dose RT) or high (Cis-
high-dose RT) dose RT, or carboplatin-paclitaxel (CP)-based
chemotherapy combined with low (CP-low-dose RT) or high
(CP-high-dose RT) dose RT.
Cis-based chemotherapy included regimens with Cis
100mg/m2 (day 1) administered at weeks 1, 4, and 7 of RT;
Cis 6mg/m2 daily during the first 25 fractions of RT; Cis
40mg/m2 weekly during RT; or Cis 75mg/m2 (day 1) plus 5-
FU 1 g/m2 (days 1–4) at weeks 1 and 5 of RT with or without
two additional courses on weeks 8 and 11. CP regimens
comprise carboplatin AUC2 and paclitaxel 50mg/m2 adminis-
tered weekly during the period of RT.
RT groups were categorized into a low-dose group with
a planned radiation dose above 41.4 Gy, as used in neoad-
juvant schedules, and not exceeding 50.4 Gy, and a high-
dose group with a RT dose above 50.4 Gy, in daily frac-
tions of 1.8–2Gy. Patients were treated by means of exter-
nal-beam radiation, usually given with 4–6MV photon
linear accelerators. RT was given by a standard 3 or 4-field
technique or by an intensity-modulated radiotherapy
(IMRT) or volumetric modulated arc therapy (VMAT) tech-
nique depending on availability in the treatment period.
Depending on local institutional policies, the Gross Tumor
Volume (GTV) of the primary tumor was delineated on the
planning-CT and expanded to a Clinical Target Volume
(CTV) by a margin of up to 3 cm in craniocaudal direction.
Involved lymph nodes were also delineated in the CT scan
and expanded to a CTV. The peri-esophageal area at the
level of the CTV was included to ensure inclusion of adja-
cent draining lymph nodes. In cervical EC (CEC), sometimes
Elective Nodal Irradiation (ENI) was added to include
parts of the (lower) neck levels. The CTV’s were combined
and expanded by a margin up to 1 cm into a Planning
Target Volume (PTV). Radiation dose was prescribed to
the PTV.
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Data collection
All consecutive patients with proximal esopageal cancer and
treated with definitive CRT were identified from the popula-
tion-based Netherlands Cancer Registry. Next, we collected
the data from the medical records of the Radiotherapy insti-
tutes and Medical Oncology and Surgical Oncology depart-
ments. Patient demographics, tumor characteristics,
treatment details, tumor response, and vital status were col-
lected retrospectively from the medical records. Data collec-
tion was performed between April 2017 and May 2018.
Outcomes
The primary endpoint was OS, defined as the period from
start date of RT to the date of death from any cause, or cen-
sored at the date of last follow-up. Secondary endpoints
included safety, and tumor response three months after com-
pleting CRT as assessed by the local study investigators by
means of clinical investigation and/or imaging. Patients were
generally examined in regular follow-up according to
national guidelines at 4–8weeks after completion of CRT,
and every 3 months in the first year, with escalating interval
up to 5 years or until death. Safety was scored by the study
investigators using Common Terminology Criteria for
Adverse Events (CTCAE) Version 4.0 [24]. Acute toxicity was
defined as adverse events occurring during CRT or within
90 days after last radiation dose. Late toxicity was scored if
the toxic event appeared at least 90 days after the end
of therapy.
Statistical analyses
Baseline characteristics were analyzed using the ANOVA test
or Kruskal–Wallis test for continuous variables, and the Chi-
squared test or Fisher exact test for categorical variables.
Median follow-up was estimated using the inverse
Kaplan–Meier method. OS was calculated by the
Kaplan–Meier method. Differences in OS between the CRT
regimens were determined using the logrank test, and uni-
variably and multivariably in Cox proportional hazards
regression models. OS analyses were performed based on an
intention-to-treat analysis, i.e. all included patients, and a
per-protocol analysis, including patients who completed
treatment as planned, defined as undergoing all fractions of
RT and all cycles of chemotherapy, excluding dose interrup-
tion or reductions.
For the multivariable analyses of OS, both a classical
model as well as a post hoc propensity score (PS) weighted
model were used, because the events per variable ratio was
borderline for a classical model, i.e. eight (all variables con-
sidered) to twelve (multivariable model) [25]. Confounding
factors included in the PS weighted model were age, gender,
WHO performance status, comorbidity, cT stage, cN stage,
tumor location and tumor length. Variables with p< .10 in
the univariable analysis were subsequently selected for the
classical Cox regression analysis. Cis-low-dose RT was
assigned as reference group, regarded as standard for
definitive CRT regimen in EC [8]. Considering the numbers of
covariables, PS weighting was performed to balance the pre-
treatment covariable distributions of the different treatment
groups. First, a PS for each patient was calculated by gener-
alized boosted regression using the same variables as
included in the univariable model. Four different stopping
rules, based on summary statistics (i.e. maximum or mean) of
absolute standardized bias or the Kolmogorov–Smirnov stat-
istic which compare the means or the distributions of the
covariates between treatment groups [26,27], overlap
between the groups, and the balance was investigated. After
calculating the PS weights, they were used in a weighted
survival analyses to calculate the effect of the different treat-
ments on OS. Because of the small sample size of the
CP-high-dose RT group (N¼ 12), sensitivity analyses were
performed excluding this group.
Differences in response and (grades 3–5) adverse events
were evaluated using the Chi-square test. Additionally, a
multilevel (patients within centers) logistic regression analysis
on grades 3–5 acute and late toxicity by definitive CRT regi-
men was performed, including calender period and GTV (sur-
rogate for RT field size) on patient level as confounding
factors. Since causality of adverse events with either radio-
therapy or chemotherapy could not be distinguished in most
cases, no separate analysis of toxicity for treatment modality
was performed.
Results
In total, 200 patients were included. Fifty-four patients (26%)
underwent Cis-low-dose RT, 39 patients (19.5%) Cis-high-
dose RT, 95 patients (47.5%) CP-low-dose RT, and 12 patients
(6%) CP-high-dose RT. Cis-based therapy was replaced by CP
in most sites after 2010 (Supplementary Figure S1). Baseline
characteristics are presented in Table 1. Median age was
higher in the CP-low-dose RT group compared with the
other groups (p¼ .02). Comorbidity frequencies were com-
parable between treatment groups (p¼ .27). Patients in the
Cis-high-dose RT group had the lowest probability of com-
pleting CRT (59%). In the CP-low-dose RT group, 93% of the
patients received 50.4 Gy, and 98% in the Cis-low dose RT
group received 50–50.4 Gy (data not shown). Six of the 67
patients with an incomplete response underwent sal-
vage surgery.
Survival
Median follow-up of all patients was 62.6months (95% confi-
dence interval [CI]: 47.9–77.2months). During the study
period, 139 deaths occured including 96 (69%) due to seque-
lae of the esophageal tumor, 6 (4%) as a result of toxicity, 18
(13%) due to other causes, and 19 (14%) due to unknown
causes. Median OS was 21.9months (95% CI: 16.9–27.0
months) for the total population, and 21.9 (95% CI: 17.7–26.1
months), 17.2 (95% CI: 0.0–48.1 months), 23.2 (95% CI:
15.6–30.8 months), and 15.7 (95% CI: 8.3–23.2 months)
months in Cis-low-dose RT, Cis-high-dose RT, CP-low-dose
RT, and CP-high-dose RT groups, respectively (Figure 1,
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p logrank¼ .88). Three-year OS rates were 35% (95% CI:
22–48%) in the Cis-low-dose RT group compared to 46%
(95% CI: 30–61%), 40% (95% CI: 30–50%), and 33% (95% CI:
10–59%), in Cis-high-dose RT, CP-low-dose RT, and CP-high-
dose RT group, respectively. Per-protocol analysis showed
comparable results (Supplementary Figure S2,
p logrank¼ .76).
After correction for potential confounders, no difference
in OS between the four treatment schemes was observed
(Table 2). Male gender, WHO performance status 2-3,
unknown T stage (Tx), and Nþ stage were independent
unfavorable prognostic factors for OS. OS was significantly
higher in patients with tumors located in the upper thoracic
segment compared to patients with cervical tumors [hazard
ratio (HR) 0.61, 95% CI: 0.42–0.88]. The PS weighted cox
regression analysis showed no significant difference in OS
between treatment groups. Sensitivity analyses excluding CP-
high-dose RT group showed a better balance of the PSs and
overlap between the groups, confirming that there were no
statistically significant differences in OS.
Univariable analysis showed no difference in OS between
patients treated with Cis-based versus CP-based regimens
Table 1. Baseline characteristics of 200 consecutive patients with proximal esophageal cancer treated with definitive chemoradiation (2004–2014).
Cis-low-dose RT Cis-high-dose RT CP-low-dose RT CP-high-dose RT
ap ValueN¼ 54 (26%) N¼ 39 (19.5%) N¼ 95 (47.5%) N¼ 12 (6%)
Age at diagnosis .02
Median, years (range) 62 (35–77) 61 (30–81) 66 (49–85) 62 (44–76)
70 years 6 (11%) 6 (15%) 31 (33%) 3 (25%)
Gender .27
Male 38 (70%) 22 (56%) 59 (62%) 10 (83%)
WHO performance status .55
0 21 (39%) 12 (31%) 28 (29%) 4 (33%)
1 30 (56%) 20 (51%) 50 (53%) 8 (67%)
2–3 2 (4%) 2 (5%) 8 (8%) 0
Unknown 1 (2%) 5 (13%) 9 (10%) 0
Comorbidity .27
Any 30 (56%) 18 (46%) 61 (64%) 7 (58%)
Cardiovascular 13 (24%) 11 (28%) 31 (33%) 6 (50%)
Pulmonary 4 (7%) 6 (15%) 7 (7%) 0
Previous malignancy 12 (22%) 1 (3%) 23 (24%) 1 (8%)
None 24 (44%) 21 (54%) 34 (36%) 5 (42%)
Tumor differentiation grade .04
G1 3 (6%) 2 (5%) 4 (4%) 0
G2 9 (17%) 12 (31%) 33 (35%) 4 (33%)
G3 19 (35%) 11 (28%) 14 (15%) 0
Gx 23 (43%) 14 (36%) 44 (46%) 8 (67%)
Clinical T stage .20
T1-3 31 (57%) 22 (56%) 63 (66%) 6 (50%)
T4 19 (35%) 9 (23%) 26 (27%) 5 (42%)
Tx 4 (7%) 8 (21%) 6 (6%) 1 (8%)
Clinical N stage .47
N0 17 (31%) 10 (26%) 27 (28%) 6 (50%)
Nþ 35 (65%) 27 (69%) 67 (71%) 6 (50%)
Nx 2 (4%) 2 (5%) 1 (1%) 0
Tumor location .03
Cervical (<18 cm) 15 (28%) 21 (54%) 27 (28%) 4 (33%)
Upper thoracic (18–24 cm) 39 (72%) 18 (46%) 68 (72%) 8 (67%)
GTV, cm3 .11
Median (range) 34.9 (2.4–190.5) 39.5 (10.3–130.8) 31.5 (6.8–142.0) 55.2 (29.0–106.0)
Unknown 16 (30%) 11 (28%) 9 (10%) 3 (25%)
Radiation dose parameters
Median total radiation dose applied, Gy (range) 50.4 (23.4–50.4) 70.0 (12.0–70.0) 50.4 (37.8–50.4) 61.6 (54–70.0) <.001
Median fraction dose, Gy (range) 1.8 (1.8–2.0) 2.0 (1.8–2.8) 1.8 (1.8–2.5) 2.0 (1.8–2.2)
Median number of applied fractions (range) 27 (13–28) 35 (6–35) 28 (20–28) 30 (28–35)
CRT completed as planned .24
Yes 44 (82%) 23 (59%) 68 (72%) 10 (83%)
No 7 (13%) 14 (36%) 20 (21%) 2 (17%)
Unknown 3 (6%) 2 (5%) 7 (7%) 0
RT completed as planned .24
Yes 53 (98%) 34 (87%) 89 (94%) 11 (92%)
No 1 (2%) 5 (13%) 5 (5%) 1 (8%)
Unknown 0 0 1 (1%) 0
Chemotherapy completed as planned .61
Yes 44 (82%) 25 (64%) 69 (73%) 10 (83%)
No 7 (13%) 11 (28%) 19 (20%) 2 (17%)
Unknown 3 (6%) 3 (8%) 7 (7%) 0
Percentages may not add up to 100 because of rounding.
aContinuous variables are calculated with the ANOVA-test or Kruskal–Wallis test. Categorical variables are calculated with the Chi-squared test or Fisher exact
test where needed.
Cis-low-dose RT: cisplatin-based chemotherapy with low-dose RT; CRT: chemoradiation; Cis-high-dose RT: cisplatin-based chemotherapy with high-dose RT; CP-
low-dose RT: carboplatin/paclitaxel with low-dose RT; CP-high-dose RT: carboplatin/paclitaxel with high-dose RT; GTV: gross tumor volume as delineated on the
CT scan used for radiation treatment planning; CRT: chemoradiation; RT: radiotherapy.
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Figure 1. Kaplan–Meier curves for overall survival by treatment, intention-to-treat analysis. Cis/low: cisplatin and low-dose radiotherapy; Cis/high: cisplatin and
high-dose radiotherapy; CP/low: carboplatin/paclitaxel and low-dose radiotherapy; CP/high: carboplatin/paclitaxel and high-dose radiotherapy.
Table 2. Univariable and multivariable comparison of overall survival by four definitive chemoradiation regimens, and propensity score
adjusted for overall survival.
Univariable Multivariable Propensity score weighted
HR (95% CI) p Value HR (95% CI) p Value HR (95% CI) p Value
Definitive chemoradiation regimen
Cis-low-dose RT Ref Ref Ref
Cis-high-dose RT 1.05 (0.65–1.71) .84 1.05 (0.62–1.79) .86 1.00 (0.57–1.78) .99
CP-low-dose RT 1.03 (0.69–1.55) .88 1.02 (0.67–1.56) .93 1.03 (0.68–1.57) .87
CP-high-dose RT 1.33 (0.66–2.68) .43 1.32 (0.64–2.72) .45 1.65 (0.83–3.25) .15
Age at diagnosis 1.00 (0.98–1.02) .93 — NA
Gender
Male Ref Ref NA
Female 0.78 (0.55–1.11) .17 0.65 (0.44–0.97) .04 NA
WHO performance status
0 Ref Ref NA
1 1.16 (0.80–1.68) .44 1.22 (0.83–1.80) .32 NA
2–3 1.94 (0.97–3.87) .06 2.56 (1.18–5.60) .02 NA
Unknown 1.13 (0.57–2.25) .73 1.57 (0.76–3.28) .23 NA
Comorbidity
No comorbidity Ref NA
Comorbidity 1.04 (0.74–1.45) .83 — NA
cT stage
T1–3 Ref Ref NA
T4 1.44 (0.99–2.09) .06 1.35 (0.90–2.03) .15 NA
Tx 1.54 (0.89–2.67) .13 1.85 (1.03–3.34) .04 NA
cN stage
N0 Ref Ref NA
Nþ 1.32 (0.92–1.91) .14 1.69 (1.13–2.53) .01 NA
Nx 1.00 (0.24–4.15) 1.00 0.88 (0.21–3.78) .87 NA
Tumor location
Cervical (<18 cm) Ref Ref NA
Upper thoracic (18–24 cm) 0.66 (0.47–0.94) .02 0.60 (0.42–0.86) .006 NA
Tumor length
5 cm Ref — NA
>5 cm 1.16 (0.74–1.80) .52 — NA
Obstruction or unknown 1.37 (0.93–2.01) .11 — NA
Cis-low-dose RT: cisplatin-based chemotherapy with low-dose RT; Cis-high-dose RT: cisplatin-based chemotherapy with high-dose RT; CP-low-
dose RT: carboplatin/paclitaxel with low-dose RT; CP-high-dose RT: carboplatin/paclitaxel with high-dose RT; NA: not applicable. Bold font indi-
cates significant prognostic factors of overall survival.
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(p¼ .81), or between low-dose versus high-dose RT (p¼ .64)
(data not shown). Both patients with CEC or upper thoracic
EC (UTEC) showed comparable OS between treatment
groups (p¼ .90 and p¼ .92, respectively) (Supplementary
Figure S3).
Tumor response
Response to therapy was available in 196 patients (98%)
(Supplementary Table S1). Clinical complete response was
achieved in 57%, 69%, 68%, and 75% of patients in the Cis-
low-dose RT, Cis-high-dose RT, CP-low-dose RT, and CP-high-
dose RT group, respectively. The rate of complete response
versus incomplete response was not significantly different
between the groups (p¼ .72). The rate of partial response
was comparable for the different regimens, varying between
18 and 25%.
Adverse events
Grades 3 or 4 acute adverse events occurred in 22 (41%), 19
(49%), 21 (22%), and 5 (42%) patients in Cis-low-dose RT, Cis-
high-dose RT, CP-low-dose RT, and CP-high-dose RT group,
respectively (Table 3). Dysphagia was the main contributor of
grades 3 or 4 toxicity in all groups. The incidence of acute
renal failure was higher in the Cis-groups compared with the
CP-groups. Comparable rates of treatment-related deaths
occurred in all four groups. In total, six patients died because
of treatment-related adverse events, of which two patients
during CRT and the remaining with an interval of
4.4–10.4months after start of CRT. Three patients died from
respiratory problems, one from esophageal stenosis, one
from esophageal perforation, and one from esophageal fistu-
lation. The incidence of grades 3–5 acute adverse events was
significantly lower in patients treated with CP-low-dose RT
compared to patients treated with one of other three regi-
mens (p¼ .01). The multivariable multilevel analysis con-
firmed a significantly better safety profile in terms of acute
toxicity of CP-low-dose RT versus Cis-high-dose RT (OR 3.78
(95% CI: 1.31–10.87); p¼ .01), and a trend toward a favorable
safety profile of CP-low-dose RT versus Cis-low-dose RT
(p¼ .10, Table 4). The occurrence of grades 3–5 late toxicities
was not different between treatment groups (p¼ .32), con-
firmed in multivariable analysis (Table 4).
Discussion
Definitive CRT is the current standard of care in patients with
proximal EC [7,8]. Although there seems to be general con-
sensus regarding the need for CRT, there is significant vari-
ation in the design of this multimodality therapy. In this
study, no statistically significant difference in OS could be
determined between four contemporary CRT regimens. A
firm conclusion is however not possible due to the small
sample size. However, CP showed a better safety profile
compared with Cis-based groups.
Limited randomized series on CRT regimens in EC investi-
gated either unknown numbers of proximal EC patients [28],
or limited numbers of patients with proximal EC [29,30]. A
recent phase 3 trial in patients with EC treated with defini-
tive CRT showed no significant difference in OS between
paclitaxel plus 5-FU and Cis plus 5-FU [14]. This led to the
initiation of a phase 3 trial comparing paclitaxel plus cis-
platin, CP, and paclitaxel plus 5-FU concurrent with RT for
patients with EC (NCT02459457). No randomized trials have
been published comparing Cis- versus CP-based CRT
schemes in patients with EC.
RT dose escalation (64.8 versus 50.4 Gy) was evaluated in
patients with EC in a randomized trial (INT-0123/RTOG 94-05)
[28]. This trial was prematurely stopped when an interim
analysis showed a higher treatment-related mortality rate in
the high-dose RT arm. Yet, seven of the 11 deaths occurred
in patients who actually had received 50.4 Gy. A recent
meta-analysis (n¼ 3736) including the before mentioned
RTOG 94-05 trial and seven retrospective studies demon-
strated better outcomes in patients with squamous cell EC
treated with definitive CRT with high dose radiotherapy
(60Gy) versus 45–59.4 Gy [31]. However, this analysis
excluded patients with incomplete dosage, receiving <45Gy.
In the era of modern RT techniques, dose escalation in CRT
for EC has been investigated in 260 patients with EC by the
randomized ARTDECO study, including 72 patients (28%)
with proximal EC. Radiation dose escalation up to 61.6 Gy
versus 50.4 Gy to the primary tumor in CP-based CRT did not
improve local control and OS [32].
To the best of our knowledge, this is the largest study
comparing Cis- versus CP-based CRT, with RT dose-escalation
regimens in patients with proximal EC in a curative treat-
ment approach. OS data in our cohort is consistent with
results of previous observational studies in cervical or prox-
imal EC exploring the effects of CRT, with 3-year OS rates of
about 35–45% [33–39]. Recently, a small retrospective single
institutional Korean study exploring the impact of radiation
dose escalation on OS showed more favorable 3-year OS
rates compared to the results in the current study, with 58%
in the high-dose RT (59.4 Gy) and 49% of patients in the
low-dose RT group (<59.4 Gy, p¼ .69) [40]. However, this
study excluded patients who had not completed treatment
as planned. In line with our results, an analysis of 789
patients with CEC from the US Cancer Data Base demon-
strated no association between radiation dose escalation and
improved OS [41]. Of note, they did not provide information
on potential confounding factors, such as chemotherapeutic
regimens and safety information. Furthermore, one Japanese
phase 2 trial [42] was conducted in 2009–2013 in 30 patients
with CEC to evaluate Cis-based high dose RT (60 Gy), demon-
strating a remarkable 3-year OS of 67%, compared with 46%
observed in this study. However, this concerned a highly
selected patient group with mostly early stage disease and
excellent performance status. Interestingly, in this series one-
third of the patients underwent salvage surgery. With a com-
parable complete response rate of 73%, the higher 3-year OS
outcome suggests a possible role for salvage surgery in
patients who fail to achieve a complete response.
Our study confirmed previous data concerning impaired
treatment compliance in patients treated with Cis-based CRT.
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Honing et al. [20] described that only 57% of patients with
EC treated with Cis-based CRT completed treatment, compar-
able with 59% of patients treated with Cis-high-dose RT in
our cohort. Remarkably, 82% of the patients in the current
study undergoing Cis-low-dose RT were able to complete
therapy. To help determine if non-adherence to Cis-high-
dose RT was responsible for OS in this group, a separate per-
protocol analysis was performed that included only patients
who completed the assigned CRT schedule (Supplementary
Figure S2). Despite this biased analysis, again no survival
advantage of the Cis-high-dose RT group could be demon-
strated. Premature treatment discontinuation was frequently
a result of side effects. Considering this study was unable to
provide survival differences between the four treatment
groups, arguments for treatment choice might be based on
the expected adverse event rates.
Table 3. Adverse events, No. (%).
Cis-low-dose RT
(N¼ 54)
Cis-high-dose RT
(N¼ 39)
CP-low-dose RT
(N¼ 95)
CP-high-dose RT
(N¼ 12)
Any
gradea
Grades
3–4 Grade 5
Any
gradea
Grades
3–4 Grade 5
Any
gradea
Grades
3–4 Grade 5
Any
gradea
Grades
3–4 Grade 5
Acute toxicity
Any 35 (65) 22 (41) 1 (2) 25 (64) 19 (49) 1 (3) 60 (63) 21 (22) 1 (1) 9 (75) 5 (42) 0
Dysphagia 22 (41) 12 (22) 0 17 (44) 11 (28) 0 30 (32) 8 (8) 0 7 (58) 4 (33) 0
Mucositis 12 (22) 3 (6) 0 5 (13) 0 0 16 (17) 5 (5) 0 2 (17) 0 0
Esophageal fistula 1 (2) 1 (2) 0 0 0 0 0 0 0 0 0 0
Esophageal perforation 1 (2) 1 (2) 0 0 0 0 0 0 0 0 0 0
Nausea 1 (2) 0 0 0 0 0 0 0 0 0 0 0
Vomiting 1 (2) 0 0 0 0 0 0 0 0 0 0 0
Diarrhea 1 (2) 0 0 0 0 0 0 0 0 0 0 0
Radiation dermatitis 11 (20) 1 (2) 0 4 (10) 0 0 13 (14) 1 (1) 0 4 (33) 0 0
Respiratory disorders 11 (20) 3 (6) 1 (2) 4 (10) 3 (8) 1 (3) 7 (7) 3 (3) 1 (1) 0 0 0
Cardiac disorders 2 (4) 1 (2) 0 0 0 0 1 (1) 0 0 0 0 0
Thromboembolic events 0 0 0 0 0 0 1 (1) 1 (1) 0 0 0 0
Anemia 2 (4) 2 (4) 0 2 (5) 1 (3) 0 1 (1) 0 0 0 0 0
Platelet count decreased 1 (2) 1 (2) 0 5 (13) 3 (8) 0 2 (2) 1 (1) 0 1 (8) 0 0
Neutrophil count decreased 5 (9) 3 (6) 0 1 (3) 1 (3) 0 2 (2) 0 0 1 (8) 0 0
Fever 2 (4) 1 (2) 0 1 (3) 0 0 4 (4) 2 (2) 0 2 (17) 1 (8) 0
Febrile neutropenia 0 0 0 0 0 0 3 (3) 3 (3) 0 0 0 0
Acute kidney injury 4 (7) 3 (6) 0 6 (15) 3 (8) 0 3 (3) 1 (1) 0 0 0 0
Hearing impaired 0 0 0 2 (5) 0 0 1 (1) 0 0 0 0 0
Neuropathy 0 0 0 0 0 0 0 0 0 0 0 0
Other 10 (19) 0 0 2 (5) 1 (3) 0 5 (5) 1 (1) 0 1 (8) 0 0
Late toxicity
Any 14 (26) 9 (17) 0 18 (46) 10 (26) 1 (3) 30 (32) 16 (17) 1 (1) 7 (58) 3 (25) 1 (8)
Dysphagia/esophageal stenosis 14 (26) 9 (17) 0 13 (33) 9 (23) 0 25 (26) 13 (14) 1 (1) 7 (58) 2 (17) 0
Esophageal fistula 0 0 0 1 (3) 1 (3) 0 2 (2) 2 (2) 0 1 (8) 0 1 (8)
Esophageal perforation 0 0 0 1 (3) 0 1 (3) 0 0 0 0 0 0
Tracheal obstruction 0 0 0 1 (3) 1 (3) 0 1 (1) 1 (1) 0 1 (8) 1 (8) 0
Other 3 (6) 0 0 4 (10) 1 (3) 0 7 (7) 2 (2) 0 1 (8) 1 (8) 0
Adverse event terms preprinted in the case report forms (all other adverse events were coded by preferred terms using Common Terminology Criteria for
Adverse Events (CTCAE) Version 4.0.). Cis-low-dose RT: cisplatin-based chemotherapy with low-dose RT; Cis-high-dose RT: cisplatin-based chemotherapy with
high-dose RT; CP-low-dose RT: carboplatin/paclitaxel with low-dose RT; CP-high-dose RT: carboplatin/paclitaxel with high-dose RT.
aAny grade¼ grades 1–5 or unknown.
Table 4. Multivariable multilevel (patients within centers) analyses of grades 3–5 acute and late toxicity.
Grades 3–5 acute tox Grades 3–5 late tox
N (%) OR (95% CI) p Value N (%) OR (95% CI) p Value
Definitive chemoradiation regimen
Cis-low-dose RT 23 (43) 2.43 (0.83–7.08) .10 9 (17) 0.87 (0.30–2.53) .80
Cis-high-dose RT 20 (51) 3.78 (1.31–10.87) .01 11 (28) 1.62 (0.58–4.53) .36
CP-low-dose RT 22 (23) Ref 17 (18) Ref
CP-high-dose RT 5 (42) 2.41 (0.52–11.1) .26 4 (33) 1.96 (0.48–8.03) .35
Period
2004–2006 6 (21) Ref 5 (19) Ref
2007–2009 19 (35) 3.03 (0.89–10.35) .08 15 (29) 1.78 (0.52–6.14) .36
2010–2014 45 (39) 5.64 (1.66–19.16) .01 21 (18) 1.06 (0.30–3.70) .92
GTV (tertiles), cm3
25 11 (23) Ref 4 (9) Ref
25-43 20 (40) 2.82 (0.99–8.08) .05 14 (29) 3.87 (1.13–13.27) .03
>43 22 (35) 1.77 (0.65–4.81) .27 13 (22) 2.64 (0.76–9.12) .13
Unknown 17 (44) 2.49 (0.73–8.45) .14 10 (26) 3.83 (0.95–15.46) .06
Cis-low-dose RT: cisplatin-based chemotherapy with low-dose RT; Cis-high-dose RT: cisplatin-based chemotherapy with high-dose RT; CP-low-dose RT: carbopla-
tin/paclitaxel with low-dose RT; CP-high-dose RT: carboplatin/paclitaxel with high-dose RT. Bold font indicates significant prognostic factors of toxicity.
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The safety profile of CP-low-dose RT group was more
favorable than that of the Cis-based groups. One in five
patients treated with CP-low-dose RT experienced grades 3
or 4 acute adverse events, whereas half of the patients
treated in the other three groups did. In agreement, retro-
spective studies in primarily thoracic EC demonstrated that
CP-based CRT was better tolerated compared with Cis-based
CRT, again with comparable survival [20,43]. The reported
toxicity rates in the CP-based CRT groups in our study dem-
onstrated higher treatment-related grade 3 or greater toxic
event rates, as compared with data from the CP-based CRT
group in the randomized neoadjuvant CROSS trial [15].
Accordingly, we consider these toxicity data to be registered
accurately. In addition, multilevel logistic regression showed
that higher toxicity rates were registered in patients treated
in the more recent years, independent of CRT regimen (Table
4). Hence, since CP-based regimens were more common in
the contemporary era, and underreporting is expected to be
higher in the older years (OR 5.64 (95% CI: 1.66–19.16) of
grades 3–5 acute toxicity in 2010–2014 versus 2004–2006),
the observed difference in toxicity between Cis- and CP-
based regimens may in fact be larger than retrospectively
observed in this study.
In addition to the more favorable toxicity profile, CP does
not require inpatient protective hydration, in contrast to
high-dose Cis [44]. Moreover, health-related costs can be
reduced by a shift to outpatient treatment, and as such CP-
based regimens may be preferred for everyday clin-
ical practice.
The strength of this study is that we included a relatively
large number of patients with a rare disease. Since a
randomized controlled trial in a disease with this low inci-
dence is challenging, we provide the second best study
design. Moreover, this study collected long-term follow-
up data.
The retrospective design of this study is inherent with
some limitations. The observational nature of the study
makes it sensitive for bias, such as selection bias. However,
correction for institution in multilevel logistic regression ana-
lysis did not alter the odds of the occurrence of grade 3-5
toxicities per treatment regimen. We were able to realize a
fair sample size by including 200 patients with proximal EC.
According to the European Society for Medical Oncology
Magnitude of Clinical Benefit Scale (ESMO-MCBS), a HR 
0.70 is defined as a clinically meaningful benefit for treat-
ments that are not likely to be curative [45]. Although in our
study, the point estimates of the HR for the different regi-
mens approximates one (suggesting a possible OS difference
would be small), the CI’s include 0.70, meaning that our
study is not powered to state that there is no difference. We
invite other institutions and countries to study this question
as well, in order to perform a meta-analysis in the future.
In conclusion, the small sample size of this study restricts
a definitive conclusion regarding OS differences between the
CRT regimens. Based on the superior safety profile, in add-
ition to a more feasible outpatient implementation, we sug-
gest a CRT regimen with carboplatin and paclitaxel in the
curative setting for patients with proximal EC.
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